1,721,124 research outputs found
Bevacizumab in older patients with advanced colorectal or breast cancer
No full textThe incidence of colorectal and breast cancer is growing among the 550 million living people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the treatment of the advanced phase of these cancers. Although older chronological age still hampers the use of modern treatments, there is a widespread awareness that chronological and physiological (i.e. functional) ages may largely differ, and that seniority itself should not be a stringent limit for the introduction of anti-angiogenics. However, the use of bevacizumab in the general older population is questionable. There is limited evidence of a favorable risk-to-benefit ratio, with efficacy data deriving from clinical trials that selected only elderly patients in rather good health. While summarizing the recent advances, this review highlights specific clinical features characterizing those older patients who may benefit the most from receiving bevacizuma
Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy
No full textBreast cancer (BC) is the most common female cancer worldwide with approximately 10 % of new cases metastatic at diagnosis and 20-50 % of patients with early BC who will eventually develop metastatic disease. Bone is the most frequent site of colonisation and the development of skeletal metastases depends on a complex multistep process, from dissemination and survival of malignant cells into circulation to the actual homing and metastases formation inside bone. Disseminated tumor cells (DTCs) can be detected in bone marrow in approximately 30 % of BC patients, likely reflecting the presence of minimal residual disease that would eventually account for subsequent metastatic disease. Patients with bone marrow DTCs have poorer overall survival compared with patients without them. Although bone-only metastatic disease seems to have a rather indolent behavior compared to visceral disease, bone metastases can cause severe and debilitating effects, including pain, spinal cord compression, hypercalcemia and pathologic fractures. Delivering an appropriate treatment is therefore paramount and ideally it should require interdisciplinary care. Multiple options are currently available, from bisphosphonates to new drugs targeting RANK ligand and radiotherapy. In this review we describe the mechanisms underlying bone colonization and provide an update on existing systemic and locoregional treatments for bone metastases
A perspective on the current management of advanced colorectal cancer
No full textAlthough the median survival of patients with advanced disease has progressively increased, colorectal cancer remains a major worldwide health problem, with approximately 1 million new cases and 500,000 deaths every year. At the 2013 World Congress on Gastrointestinal Cancers, investigators have recently dealt with many clinically relevant questions, such as the preferred biologic drug to be used upfront in patients with KRAS wild-type colorectal tumors, the optimal treatment intensity, the most suitable maintenance strategy, the need for deeper molecular information when using EGFR inhibitors and the use of antiangiogenic drugs in the elderly. Briefly summarizing all the news coming from this moving landscape, this article focuses on the results of the major randomized Phase III trials presented at the meeting. © 2013 Future Medicine Ltd
Sinusoidal endothelial flogosis in mild to moderate rejection after ortopic liver transplantation(OLTx)
No full textBrain metastases from gastrointestinal tumours: Tailoring the approach to maximize the outcome
No full textSteps ahead in the treatment of advanced colorectal cancer: Past, current and possible future scenarios
No full text
Note sulla progressiva costruzione giurisprudenziale della disciplina penale del fenomeno del c.d. sexting
No full textIl contributo cerca di ricostruire l’articolata opera di tessitura giurisprudenziale della disciplina del fenomeno del c.d. sexting ad opera soprattutto della Corte di cassazione, attraverso importanti ravvicinate pronunce, anche a sezioni unite. Oggetto di indagine sono analiticamente tutte le diverse fattispecie concrete presenti nella prassi dall’autoproduzione alla produzione, dalla conservazione alla divulgazione delle immagini intime. Rispetto a tali diverse fattispecie si sono cristallizzati talvolta orientamenti restrittivi dell’area del penalmente rilevante, in linea d’altronde con la dottrina quasi unanime, talaltra approcci ben più rigorosi, anch’essi non di rado condivisi in dottrina. Il contributo allora cercherà di sottoporre a riflessione critica le soluzioni ermeneutiche prospettate per queste diverse ipotesi, sottolineando gli approdi pregevoli e le persistenti criticità nella giurisprudenza di legittimità sviluppatasi su questo fenomeno
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
